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PURPOSE. While nitric oxide (NO) donors are emerging as treatments for glaucoma, the
mechanism by which NO lowers intraocular pressure (IOP) is unclear. NO activates the
enzyme guanylyl cyclase (GC) to produce cyclic guanosine monophosphate. We studied the
ocular effects of inhaled and topically applied NO gas in mice and lambs, respectively.
METHODS. IOP and aqueous humor (AqH) outflow were measured in WT and GC-1a subunit
null (GC-1/) mice. Mice breathed 40 parts per million (ppm) NO in O2 or control gas (N2/
O2). We also studied the effect of ocular NO gas exposure (80, 250, 500, and 1000 ppm) on
IOP in anesthetized lambs. NO metabolites were measured in AqH and plasma.
RESULTS. In awake WT mice, breathing NO for 40 minutes lowered IOP from 14.4 6 1.9 mm
Hg to 10.9 6 1.0 mm Hg (n ¼ 11, P < 0.001). Comparable results were obtained in
anesthetized WT mice (n ¼ 10, P < 0.001). In awake or anesthetized GC-1/ mice, IOP did
not change under similar experimental conditions (P ‡ 0.08, n ¼ 20). Breathing NO
increased in vivo outflow facility in WT but not GC-1/ mice (þ13.7 6 14.6% vs. 12.1 6
9.4%, n ¼ 4 each, P < 0.05). In lambs, ocular exposure to NO lowered IOP in a dose-
dependent manner (0.43 mm Hg/ppm NO; n ¼ 5 with 40 total measurements; P ¼ 0.04)
without producing corneal pathology or altering pulmonary and systemic hemodynamics.
After ocular NO exposure, NO metabolites were increased in AqH (n ¼ 8, P < 0.001) but not
in plasma.
CONCLUSIONS. Breathing NO reduced IOP and increased outflow facility in a GC-dependent
manner in mice. Exposure of ovine eyes to NO lowers IOP.
Keywords: intraocular pressure, nitric oxide, soluble guanylyl cyclase
Glaucoma is a leading cause of blindness worldwide with anestimated 80 million cases diagnosed by 2020.1 Primary
open angle glaucoma (POAG) is the most prevalent type of
glaucoma.2 Risk factors for the development of POAG include
increased intraocular pressure (IOP), age, race, and genetic
factors.3–5 The only risk factor currently amenable to treatment
is increased IOP. Several classes of drugs are available to treat
glaucoma,6 but they provide only incomplete protection from
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optic nerve deterioration. These considerations emphasize the
need for novel therapeutic approaches to lower IOP.
Nitric oxide (NO) activates the heterodimeric enzyme
guanylyl cyclase a1b1 (GC-1), resulting in increased levels of
cyclic guanosine monophosphate (cGMP).7 Previous genetic
and epidemiologic studies implicate decreased activity of the
NO-cGMP signal transduction pathway in POAG pathogene-
sis.8–13 NO-cGMP signaling regulates aqueous humor (AqH)
outflow from the anterior chamber through the trabecular
meshwork and the Schlemm’s canal,14–18 possibly by decreas-
ing trabecular meshwork (TM) cell volume,19 decreasing
Schlemm’s canal cell volume,20 and by relaxing cells in the
canalicular outflow system.21 In addition, inhibition of
endogenous NO production reduced the AqH outflow rate
through the trabecular meshwork cells in human eyes,22 and
overexpression of NO-synthase 3 (NOS3) was associated with
increasing pressure-dependent drainage and decreased IOP in
murine eyes.23 In contrast, pressure-dependent drainage was
reduced and IOP increased in NOS3-deficient mice.24 Based on
these findings, the NO-cGMP signaling system is emerging as
an attractive pathway to target increased IOP.25–28 For
example, adding an NO-releasing moiety to dexamethasone
prevented the increase in IOP observed in rabbits treated
topically with dexamethasone itself.10,24 Evidence that GC-1 is
important in POAG pathogenesis comes from a candidate gene
association study in which an intergenic variant (rs11722059)
in the GUCY1A3/GUCY1B3 region (containing the genes
encoding the a1 and b1 GC-1 subunits) was associated with a
subset of POAG patients (women with early paracentral visual
field loss).29 Furthermore, mice that are deficient in GC-1a
develop open-angle glaucoma.29 In recent clinical trials,
latanoprostene bunod (LBN, Vyzulta; Bausch þ Lomb, Roch-
ester, NY, USA), an IOP-lowering agent that combines a
prostaglandin analogue with a NO-donating moiety, lowers
IOP in POAG patients.30–32
Inhaled NO is a Food and Drug Administration (FDA)-
approved therapy for pulmonary hypertension of hypoxic
newborns33 and is under development as a treatment for other
cardiovascular diseases. Breathing up to 80 ppm NO lowers
pulmonary but not systemic blood pressure.34 The therapeutic
effect of breathing NO in the cardiovascular system is GC-1–
dependent.35
The objective of this study was to determine whether
gaseous NO delivered via inhalation in mice or by topical
application to the ovine eye without a pharmaceutical carrier
lowers IOP. In addition, we sought to determine whether the
effects of NO on IOP were mediated by GC-1, identifying GC-1
as a therapeutic target to lower IOP in glaucoma.
METHODS
All experiments were performed in compliance with the ARVO
Statement for the Use of Animals in Ophthalmic and Vision
Research and were approved by the Massachusetts General
Hospital Institutional Animal Care and Use Committee. Equal
numbers of both sexes were used throughout the experiments
(mice and lambs respectively).
Animal Preparation and Inhaled NO Gas Delivery
in Mice
We studied 12- to 18-week-old male and female 129S6 wild-
type (WT) mice (Taconic, Inc. Hudson, NY, USA) and 129S6
mice deficient in the a1-subunit of GC-1 (GC-1
/).36 Anesthe-
sia was induced with isoflurane in 90% oxygen (O2)/10%
nitrogen (N2) using a standardized anesthesia protocol that
maintains IOP at a constant level (isoflurane 5% for 15 seconds,
3% for 1 minute, 2% for 1 minute, and subsequently 1.5%). At
the final dose of isoflurane, animals breathed spontaneously via
a mask. Animals were immobilized in a prone position during
the experimental procedures. Mice breathed either 40 parts
per million (ppm) NO in 90% O2/10% N2 or 90% O2/10% N2
(control gas) at a gas flow rate of 1000 mL/minute. NO levels
(40 ppm) were continuously monitored, using a chemilumi-
nescence analyzer (Sievers 280i; GE Analytical Instruments,
Boulder, CO, USA).37
IOP Measurements in Anesthetized and Awake
Mice
Rebound tonometry (iCare, Vantaa, Finland) was used to
measure IOP in anesthetized mice at baseline and 10 minutes
after breathing either NO or control gas (Supplementary Fig.
S1).
Because isoflurane lowers IOP,38 we also measured ocular
tension in awake WT and GC-1/ mice breathing NO or
control gas. Prior to the study, mice were acclimated to manual
handling for 3 weeks. During the first week, animals were
acclimated to manual handling by holding them by the scruff of
their neck for 5 to 10 minutes daily. The following week,
animals were familiarized with the probe of the rebound
tonometer. Murine eyes were topically anesthetized by
proparacaine hydrochloride (0.5%; Bausch þ Lomb, Inc.) eye
drops (one drop per eye). Ten minutes later, mice were
manually restrained and exposed to the rebound tonometer.
During the third and last week, the animals were placed in the
incubation chamber (World Precision Instruments, Sarasota, FL
USA) and exposed to O2 (100%). At predefined time points (0,
40 minutes) animals were removed, restrained and their IOP
was measured. After 3 weeks of training, topical anesthesia was
no longer used, animal behavior remarkably improved and
experiments were conducted. Mice were placed in an
anesthesia induction chamber and exposed to either 40 ppm
NO in 90% O2/10% N2 or the control gas via a gas inlet at a flow
rate of 1000 mL/minute. A gas outlet was open to the
environment to maintain the induction chamber at ambient
pressure. IOP was measured at baseline and 40 minutes after
starting the treatment.
Ex Vivo Mouse Eye Perfusion Protocol to Measure
AqH Outflow Rates
A previously established mouse eye perfusion protocol was
modified slightly for the present study.39,40 A 5.5 mM D-glucose
(DBG) in Dulbecco’s PBS was used as mock AqH for
perfusions. Enucleated eyes from GC-1/ or WT mice were
fastened to a post in a perfusion chamber using cyanoacrylate
gel. Anterior chambers were then cannulated using a 33-gauge
needle (World Precision Instruments), guided by a microma-
nipulator and viewed using a stereo microscope. During the
cannulation procedure, eyes were stabilized using a 0.5-mm
curret. The needle was connected by pressure tubing to a 50-
lL glass syringe (World Precision Instruments), which was
mounted in a mini-pump (model 33; Harvard Apparatus,
Holliston, MA, USA) and output was controlled by custom
software written in LabVIEW (National Instruments, Newbury,
UK). The software recorded pressure readings from a Honey-
well transducer (model 142PC01G; Honeywell, Fort Washing-
ton, PA, USA) that was open to the anterior chamber via a three
way stop cock connecting tubing between syringe pump and
eye. The computer controlled pump maintained desired
pressure steps, adjusting flow rate over time. After a 45-
minute equilibration period at 8 mm Hg, using a column of
fluid to hold pressure and allow drug/vehicle to access outflow
tissues, the software was activated and eyes were perfused for
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20 minutes at each of 4 pressure steps (4, 8, 15, 20 mm Hg). To
calculate flow rate at each pressure step, a minimum of 10
minutes of stable measurements was used.
Outflow Facility Analysis
To calculate outflow facility (C), the modified Goldmann
equation was used: F ¼ C(IOP) þ Fu where F represents the
flow rate at each pressure step and Fu is an estimate of the
pressure-independent outflow rate. This equation is only valid
in experimental conditions such as with ex vivo perfusion of
enucleated eyes when episcleral venous pressure and AqH
inflow is zero. In our experimental paradigm, F reaches
equilibrium at each level of IOP, and C and Fu are independent
of IOP. The value of C is calculated from the slope of the best-fit
linear regression of the flow/pressure relationship.
Measurement of Conventional Outflow Facility in
Anesthetized Mice
Outflow facility measurements were performed as previously
described.41 Calibration of the flow-through pressure was
completed by calculating the pressure of water at two
different heights (2.8 mm Hg and 51.4 mm Hg). The
transducer was connected to both a reading box to enable
digital data transfer to a computer, and a 100-lL syringe
(Hamilton), loaded into a microdialysis infusion pump for
continuous injection of 0.9 % saline. Mice were anesthetized
with isoflurane using the same standardized protocol
described above. The anterior chamber was cannulated with
a 33-gauge ½-inch stainless steel needle attached to the
transducer (ICU Medical, Inc., San Clemente, CA, USA) and
pump. Pressure was set at 15, 25, or 35 mm Hg and
corresponding outflow capability (lL/minute) was recorded
every second for 5 minutes. In the subsequent 10 minutes, 40
ppm NO was added to the inhaled gas and outflow capability
was recorded as well as for another 5 minutes after turning off
NO. Normalizing outflow rate (lL/minute) to changes in IOP
pressure (mm Hg) provided outflow facility measurements
(lL/minute/mm Hg).
Animal Preparation and Hemodynamic
Monitoring in Anesthetized Lambs
We studied five 3- to 4-month-old Polypay lambs, from a
caesarean-derived, specific pathogen-free sheep flock (New
England Ovis, Dover, NH, USA). Animals weighed 33 6 2 kg
(mean 6 SD). A venous catheter was placed into the jugular
vein and both corneas of each lamb were treated with a single
dose of NO (80, 250, 500, or 1000 ppm) for 60 minutes on
each of four different days (see below for description of gas
delivery system). Between experiments, lambs were allowed to
recover for at least 2 days. On the last day, lambs were
anesthetized and a pulmonary catheter was used to measure
the pulmonary arterial pressure, and an arterial catheter was
used to measure the systemic blood pressure, during treatment
with 1000 ppm NO.37,42 Hemodynamic parameters were
measured as previously described.37,42,43
Use of a Custom-Made Device to Deliver NO to the
Eyes of Lambs
Commercially available swim goggles were modified to deliver
NO directly to the cornea (Supplementary Fig. S3). This device
allowed the direct exposure of the eyes to NO, without further
dilution by air. At the beginning of the experiment, the device
was placed over both eyes. Eyes were treated with NO (80,
250, 500, or 1000 ppm NO in air) or control gas (air) at a flow
rate of 500 mL/minute for 1 hour. The fraction of oxygen in air
was measured continuously (MiniOX; Ohio Medical, Gurnee,
IL, USA) to maintain 21% oxygen in the gas mixture. The gas
outlet remained open to maintain normal ambient pressure.
IOP was measured every 15 minutes by applanation tonometry
after topical saline application to hydrate the ocular surface
(Tono-Pen XL; Reichert Technologies, Inc., Depew, NY, USA).
Biochemical Analyses of Ovine Blood and AqH
Samples
Ovine blood samples were obtained through a venous catheter
at baseline, 45 minutes after topical exposure to the control
gas, and after a 1-hour exposure to either NO or the control
gas. AqH was sampled in lambs that were treated with 1000
ppm NO using a 25-gauge needle immediately after euthanasia
(1 hour after ceasing topical NO delivery). NO oxidation
products (nitrate, nitrite) and cGMP levels were measured in
both ovine plasma (Supplementary Fig. S2) and AqH samples as
previously described.42
Measurement of the Corneal Thickness Before and
After Exposure to 1000 ppm NO Using Ultrasound
Ultrasound biomicroscopy images were acquired using a 40
MHz probe (Vevo 770; FUJIFILM-VisualSonics, Toronto, Cana-
da). The probe was positioned perpendicular to the cornea and
2-dimensional images were acquired. The greatest thickness of
the cornea was recorded.
Microscopy
After euthanasia, the sheep globes were enucleated and
immersion-fixed for 24 hours in PBS containing paraformalde-
hyde (4%). The fixed globes were sectioned in the dorsoventral
sagittal plane, serially sectioned at a thickness of 5 lm, and
stained with hematoxylin and eosin (H&E). A pathologist
masked to the type of intervention analyzed lamb corneas
using a brightfield microscope (BX43; Olympus Corp., Melville,
NY, USA). Images were captured using a mounted digital
camera (DP72; Olympus Corp.) with image analysis software
(CellSence Dimension 1.4; Olympus Corp.).
Statistical Analyses
All data are expressed as mean 6 SD. Statistical analyses were
performed using commercial software (GraphPad Prism 6;
GraphPad Software, La Jolla, CA, USA). Variables were tested
for normality using the Shapiro-Wilk test. Two-group compar-
isons were performed using the Student’s t-test (paired or
unpaired, as appropriate) for normally distributed variables.
For multigroup comparisons, ANOVA was used. For variables
that were measured over time (or at different pressures), a
repeated measures ANOVA was used. The exact analyses for
each comparison are described in detail below. All analyses
were adjusted for multiple comparisons using the Bonferroni
correction, where the P value threshold for significance was
0.05/(number of comparisons).
A paired t-test was used to compare differences in murine
IOP levels at baseline and after NO treatment in the WT and
GC-1/mice. We performed 2-way repeated measures ANOVA
to compare AqH outflow rates between WT and GC-1/mice
at various IOP levels. Because the interaction P value between
genotype and pressure was significant in the 2-way repeated
measures ANOVA, unpaired t-tests were performed for each
pressure to compare the two genotypes. An unpaired t-test
was used to compare differences in the outflow facility and
the percent change in outflow rate between NO-treated WT
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and GC-1/ mice. A paired t-test was performed to compare
differences in ovine IOP levels before and after exposure to
various NO concentrations. Linear regression analysis with
slope comparisons of the change in IOP before and after NO
exposure of ovine corneas was used to evaluate the dose-
response effect between various NO concentrations. Ovine
time-response experiments were analyzed by a pairwise
comparison of the 45-minute time point with 60-, 75-, 90-, or
105-minute time points, respectively, within a group using a
paired t-test. An unpaired t-test was used to compare
differences in AqH nitrate and nitrite levels between control-
treated and NO-treated eyes. Plasma nitrate, nitrite, and cGMP
levels were analyzed by a 1-way repeated measures ANOVA
including baseline, 45, 90, and 140 minute levels within each
treatment group. For hemodynamic experiments, a 1-way
ANOVAwas used to compare differences between the control-
treated, NO-treated, and post-NO treated groups (P < 0.017
was considered significant).
RESULTS
Inhaled NO Reduces IOP in WT, but not GC-1/
Mice
Breathing 40 ppm NO for 10 minutes lowered the IOP in
anesthetized WT mice (IOP before and after breathing NO, 10.0
6 0.2 mm Hg vs. 8.56 0.5 mm Hg, respectively, n¼10 each, P
< 0.001, Fig. 1A). Inhalation of NO did not affect IOP in GC-1/
mice (IOP before and after breathing NO, 9.8 6 0.3 mm Hg vs.
9.5 6 0.3 mm Hg, respectively, n¼ 9 each, P¼ 0.08, Fig. 1B).
Breathing control gas did not change IOP in anesthetized WT
mice (IOP before and after breathing control gas, 10.0 6 0.2
mm Hg vs. 9.8 6 0.3 mm Hg, respectively, n ¼ 10 each, P ¼
0.11). Similarly, control gas did not significantly affect IOP in
GC-1/mice (IOP before and after breathing control gas, 9.76
0.6 mm Hg vs. 9.3 6 0.6 mm Hg, respectively, n¼ 9 each, P¼
0.052).
Similar to results obtained in anesthetized mice, awake WT
mice breathing 40 ppm NO for 40 minutes had lower IOP
values (IOP before and after breathing NO, 14.4 6 1.9 mm Hg
vs. 10.9 6 1.0 mm Hg, respectively, n¼ 7 each, P < 0.001, Fig.
1C). Breathing NO (IOP before and after, 14.7 6 0.9 mm Hg vs.
15.4 6 1.7 mm Hg, respectively, n¼ 11 each, P¼ 0.20) for 40
minutes did not change IOP in awake GC-1/ mice (Fig. 1D).
Breathing control gas did not significantly change IOP in WT (n
¼ 7, P¼ 0.06, Fig. 1C) or GC-1/ mice (n¼ 11, P¼ 0.93, Fig.
1D).
GC-1 Modulates Conventional AqH Outflow in WT
Mice
To investigate the mechanism by which NO decreases IOP, we
measured AqH outflow rates ex vivo at various IOP levels (4, 8,
15 and 20 mm Hg) in enucleated eyes from GC-1/ and WT
mice. Ex vivo AqH outflow was higher in enucleated WT
mouse eyes at IOP levels of 15 and 20 mm Hg, respectively,
than in GC-1/ mouse eyes (outflow rates at 15 and 20 mm
Hg, 0.28 6 0.1 lL/minute vs. 0.18 6 0.07 lL/minute, P ¼
0.007 and 0.38 6 0.16 lL/minute vs. 0.21 6 0.08 lL/minute, P
< 0.0001, n ¼ 10 each, Fig. 2A). To further investigate the
ability of GC-1 to modulate ex vivo AqH outflow, the
relationship between outflow rates (uL/min) at each pressure
(mm Hg) provides a conventional outflow facility estimate (uL/
minute/mm Hg). Ex vivo conventional outflow facility was
higher in WT mouse eyes than in age-matched GC-1/ mouse
eyes (0.017 6 0.007 lL/minute/mm Hg vs. 0.008 6 0.003 lL/
minute/mm Hg, respectively, P¼ 0.005, n¼ 10 each, Fig. 2B).
Next, in vivo AqH outflow was measured at different IOP
levels (15, 25, 35 mm Hg) in both GC-1/ and WT mice.
Similar to the ex vivo observations, the AqH outflow rate was
higher in WT mice (n¼8) than in age-matched GC-1/mice (n
¼ 7; AqH outflow rates at IOP levels of 25 and 35 mm Hg: 0.49
6 0.17 lL/minute vs. 0.38 6 0.1 lL/minute, P¼0.04; and 0.67
6 0.09 lL/minute vs. 0.47 6 0.09 lL/minute, P ¼ 0.018;
respectively, Fig. 2C). Outflow facility was higher in WT mice
(n ¼ 8) than in age-matched GC-1/ mice (n ¼ 7; 0.032 6
0.017 lL/minute/mm Hg vs. 0.012 6 0.005 lL/minute/mm Hg,
P ¼ 0.0449, Fig. 2D). In addition, breathing NO increased
outflow facility in WT but not in GC-1/mice (13.7% 6 14.6%
vs. 12.1% 6 9.4%, n¼ 4 each, P < 0.02, Fig. 2E).
Exposure of the Cornea to NO Lowers the IOP in
Anesthetized Lambs
To further test that NO by itself can alter IOP, anesthetized
lambs were treated with inhaled NO (80 ppm). In contrast to
the results observed in mice, breathing NO for 60 minutes did
not lower the IOP in healthy lambs (data not shown).
We next examined whether direct NO exposure to lamb
eyes would lower IOP. Modified swim goggles were placed
over both eyes and NO was delivered in air without admixture
by room air. Exposing lamb eyes to 1000 ppm NO for 60
minutes lowered IOP (before versus after application of 1000
ppm NO: 10.2 6 1.8 mm Hg vs. 7.0 6 1.2 mm Hg, n ¼ 10
measurements, P < 0.0001, Fig. 3A). Next, lamb eyes were
exposed to various NO concentrations of 80, 250, 500, and
1000 ppm. Topical exposure of the lamb cornea to NO
lowered IOP in a dose-dependent manner (0.43 mm Hg/ppm
NO, Fig. 3B). cGMP levels in the AqH were below the detection
limit, before and after topical administration of NO gas.
To investigate whether the IOP-lowering effect of topical
NO was time-dependent and reversible, IOP measurements
were performed during and after NO exposure. When
administering 80, 250, 500, or 1000 ppm NO, IOP values
decreased as early as 15 minutes after commencing exposure
(Fig. 3C). Upon terminating NO treatment, IOP returned to
baseline levels within 30 minutes (Fig. 3C).
The ovine central corneal thickness was measured before
and after a 1-hour exposure to 1000 ppm NO using ultrasound.
Lambs aged 3- to 4-months had a central corneal thickness of
approximately 570 lm, similar to what is typically observed in
humans (Fig. 5A). The corneal thickness was similar before and
after exposure to 1000 ppm NO (n ¼ 3, P ¼ 0.52,
Supplementary Fig. S4).
Topical NO Exposure Does Not Induce Systemic
Side Effects in Lambs
To investigate whether topical NO exposure was associated
with systemic side effects, hemodynamic parameters including
heart rate, mean arterial pressure, mean pulmonary arterial
pressure, pulmonary capillary wedge pressure, central venous
pressure, and cardiac output were monitored before, during,
and after exposing the corneas to 1000 ppm NO. Systemic and
pulmonary hemodynamic parameters did not change (n¼ 6, P
values from 0.58 to 0.98, Supplemental Material, Table S1).
Similarly, when administered topically, NO gas did not affect
cGMP levels or the NO metabolites nitrate and nitrite in plasma
(Supplementary Fig. S2). In contrast, nitrate and nitrite levels
of NO-treated eyes were elevated in AqH when compared to
control gas-treated eyes (nitrate: control [n¼6] versus NO [n¼
8]; P < 0.001, nitrite: control [n ¼ 6] versus NO [n ¼ 8], P <
0.001, Fig. 4).
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Exposure to High Levels of NO Did Not Cause
Corneal Injury
To assess whether exposure of the lamb’s eyes to NO results in
corneal changes, lamb eyes were exposed to 1000 ppm NO gas
(a level 12.5 times higher than the maximum dose commonly
used for inhalation therapy33 for 1 hour. Corneas from both
control gas (Fig. 6, panel 1) and NO-treated lamb eyes (Fig. 6,
panels 2–4) maintained their structural integrity: no micro-
scopic lesions to the various corneal layers were observed.
Minor foci of keratinization were observed in both control gas-
and NO-treated eyes, suggesting that these small lesions were
not treatment-related.
DISCUSSION
In this study, we provide evidence that NO can directly lower
IOP in mice and lambs. Breathing NO decreased IOP and
increased conventional AqH outflow in WT mice but not GC-
1/ mice. Our results in GC-1/ mice demonstrate that the
ability of NO to lower IOP and increase AqH outflow is
dependent on GC-1, identifying GC-1 as a therapeutic target for
lowering IOP. In addition, topical NO exposure of lamb’s eyes
lowered IOP in a transient and dose-dependent manner within
15 minutes without altering corneal structure or affecting
systemic hemodynamics.
The NO-releasing compound LTB combines a prostaglan-
din analogue with a nitrate moiety. It is metabolized in situ to
latanoprost acid and an organic nitrate, which has additional
IOP-lowering effects. LTB lowered IOP in clinical phase 3
trials30–32 and is under FDA review for the reduction of IOP in
open-angle glaucoma. In a direct comparison to latanoprost
0.005%, LTB 0.024% was superior in lowering diurnal IOP at
day 28, but the concentrations of prostaglandin analogue
were not identical. The ability of NO to directly lower IOP
supports the concept that the greater capacity of LTB than of
FIGURE 1. Breathing NO gas lowers IOP in WT but not GC-1/mice. (A) Breathing 40 ppm NO (n¼10, ***P < 0.001), but not control gas (n¼ 10,
P¼ 0.11), lowered IOP in anesthetized WT mice. (B) In contrast, breathing 40 ppm NO did not lower IOP in anesthetized GC-1/mice (n¼ 9, P¼
0.08). (C–D) Breathing control gas did not affect IOP in awake WT (n¼7, P¼0.06) or GC-1/mice (n¼11, P¼0.93). Breathing 40 ppm NO for 40
minutes lowered IOP in awake WT mice (n¼ 7, ***P < 0.001) but not in awake GC-1/ mice (n ¼ 11, P¼ 0.20). BL, baseline.
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latanoprost to lower IOP reflects a dual mechanism of action,
involving both a latanoprost-dependent effect on uveoscleral
outflow and an NO-mediated effect on conventional AqH
outflow. Breathing NO leads to increased blood levels of NO-
metabolites such as nitrite; nitrate; nitroso (RSNO, RNNO);
and nitrosyl (NO-heme), which are possible reservoirs of NO
within the bloodstream.44 Nitrite reacts with hemeproteins
and is converted to NO, making NO available for organs and
tissues.45
In addition to NO, other gasotransmitters (carbon monox-
ide [CO] and hydrogen sulfate [H2S]) can modulate cGMP
levels, lower IOP, increase retinal blood flow, or provide
retinal neuroprotection.46–52 Novel classes of oral pharmaco-
logical agents directly targeting GC—such as FDA-approved
FIGURE 2. Conventional AqH outflow is lower in GC-1/ than WT mice. (A, B) Ex vivo AqH outflow measurements in WT and GC-1/mice. AqH
outflow rates at 15 mm Hg (n¼10, *P¼0.007) and (A) 20 mm Hg (n¼10,þP < 0.0001) and (B) conventional outflow facility (n¼10, **P¼0.005)
were lower in GC-1/ mice than in age-matched WT mice. (C, D) In vivo outflow measurements in WT (n ¼ 8) and GC-1/ mice (n ¼ 7).
Confirming measurements ex vivo, outflow rate at 25 mm Hg (#P¼0.0411) and (C) 35 mm Hg (§P¼0.0018) and (D) outflow facility ($P¼0.0449)
were lower in GC-1/mice than in age-matched WT mice. (E) NO gas, delivered via inhalation to anesthetized mice increased outflow rate in WT,
but not GC-1/ animals (n¼ 4 each, P < 0.02).
NO Lowers IOP in a GC-1–Dependent Manner IOVS j September 2017 j Vol. 58 j No. 11 j 4831
riociguat53,54 (Bayer Healthcare Pharmaceuticals LLC, Berlin,
Germany) that stimulates GC synergistically with NO, or GC-
activators capable of activating oxidized NO-insensitive
GC55—are emerging as promising therapies for cardiovascular
diseases. A GC-stimulator (IWP-953) was recently reported to
increase conventional AqH outflow facility in murine eyes.40
Combining NO-donors with an GC-stimulator (IWP-953)
resulted in a dose-dependent increase in cGMP levels in
FIGURE 3. Topical exposure of eyes to NO gas lowers IOP in anesthetized lambs in a dose- and time-dependent manner. (A) IOP decreased in lambs
treated with either 80, 250, 500, or 1000 ppm NO for 1 hour, when compared to baseline; ‘‘before NO exposure’’ represents the 45-minute time
point of (C); ‘‘after NO exposure’’ represents the 105-minute time point of (C). **P < 0.01; ***P < 0.0001. (B) Dose-response analysis of the change
in IOP before (45-minute time point of [C]) and after (105-minute time point of [C]) topical NO exposure. (C) IOP values in anesthetized lambs
before, during, and up to 60 minutes after treatment with either 80 (circle); 250 (square); 500 (triangle facing up); or 1000 ppm NO (triangle
facing down). Animals received topical NO between the 45- and 105-minute time points. IOP decreased until the NO exposure was terminated. *P
< 0.05 values in the 80, 500, and 1000 ppm NO groups differ from baseline.þP < 0.05 values differ from baseline in all 80, 250, 500, and 1000 ppm
NO groups.
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primary trabecular meshwork cells.40 Since our results
identify a GC-dependent IOP lowering mechanism, GC-
activators and clinically available GC-activators may represent
novel therapeutics for lowering IOP. Whether GC mediates
the previously reported effect of NO on AqH formation,56–58
remains to be determined.
A limitation of this study is that we studied the effect of NO
gas on IOP in healthy mice and sheep, with IOPs in the normal
range. Data from the LBN clinical trials, suggest that NO, when
delivered in combination with a prostaglandin analogue, can
lower IOP in glaucoma patients.30–32 However, it remains to be
determined whether NO alone can increase AqH outflow and
lower IOP in a pathologic setting of elevated IOP. We cannot
exclude the possibility that the results will not translate to
pathologic states with increased IOP or that the IOP-lowering
ability of NO (or another gasotransmitter) depends on the
starting IOP. Our findings need to be further confirmed in a
model of experimental glaucoma. Also, the explanation of why
breathing NO reduces IOP in mice but not sheep remains to be
determined. Finally, translating administration of an IOP-
lowering drug via inhalation to the clinical may prove to be
challenging, but our data provide important proof of principle
that NO alone may favorably alter AqH dynamics.
In summary, we studied the direct effect of gaseous NO on
IOP and AqH dynamics in two different animal models, mice
and lambs. Our results demonstrate that inhaled NO increases
conventional outflow facility and reduces IOP in mice. Our
data prove, for the first time, that the effect of NO on AqH
outflow rate and IOP is mediated by GC-1, identifying GC-1 as a
potential therapeutic target for glaucoma. In addition, topical
exposure of ovine corneas to NO gas lowers IOP and increases
NO metabolites in AqH but not systemically in the ovine
plasma.
FIGURE 4. Topical exposure of ovine eyes with 1000 ppm NO is associated with increased nitrate and nitrite levels in AqH. (A) Nitrate and (B)
nitrite levels increased when lamb eyes were exposed to 1000 ppm NO gas for an hour (nitrate: control [n¼6] versus NO [n¼8], P < 0.001; nitrite:
control [n¼ 6] versus NO [n¼ 8]). ***P < 0.001.
FIGURE 5. Ultrasound measurement of lamb cornea before and after a 1-hour exposure to 1000 ppm NO. Representative ultrasound images of the
ocular anterior segment, obtained in lambs (A) before and (B) after topical eye exposure to 1000 ppm NO for 1 hour. The corneal thickness was
similar (A) before and (B) after exposure to 1000 ppm NO. The cornea, anterior chamber, and the iris are evident. Depth of the cornea did not differ
in NO-treated versus control-gas treated eyes.
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